Article Sidebar

PDF
Date Published: 28/03/2024
Abstract Views: 31
Views PDF: 31
DOI: https://doi.org/10.56535/jmpm.v49i3.665
Issue
Vol. 49 No. 3 (2024): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 3 - 2024
Section
Articles
How to Cite
Ngo, T. H., Nguyễn, T. L., Nguyễn, V. T., & Cấn, V. M. (2024). ĐÁNH GIÁ KHẢ NĂNG GÂY CHẾT TẾ BÀO UNG THƯ PHỔI CỦA VIRUS VACCINE SỞI PHỐI HỢP CISPLATIN IN VITRO. Journal of Military Pharmaco-medicine, 49(3), 87-95. https://doi.org/10.56535/jmpm.v49i3.665

ĐÁNH GIÁ KHẢ NĂNG GÂY CHẾT TẾ BÀO UNG THƯ PHỔI CỦA VIRUS VACCINE SỞI PHỐI HỢP CISPLATIN IN VITRO

Ngo Thu Hang1, , Đặng Thùy Linh, Nguyễn Văn Tân, Cấn Văn Mão
1 Vietnam Medical Military University

Main Article Content

Abstract

Objectives: This study aims to evaluate the oncolytic effects of the measles virus and Cisplatin against lung-cell carcinoma in vitro. Materials and methods: The vaccine train of the Measles virus (MeV) and Cisplatin were employed to assess the oncolytic effects on lung-cell carcinoma H460. H460 cells treated with MeV and Cisplatin were collected at 48, 72 and 96 hours to conduct the MTT assay. Results: The proportion of living cells in the treated groups was significantly lower compared to the control group (p<0.0001). Additionally, the proportion of living cells in the group treated with the MeV+Cisplatin combination was significantly lower than those with single treatment of MeV or Cisplatin (p<0.01). Conclusion: Combination treatment with the Vaccine Strain Measles virus and Cisplatin enhances oncolytic activity against lung cancer cells in vitro.

Article Details

Keywords

Ung thư phổi H460, Virus vaccine sởi, Cisplatin, MTT

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-249.
2. Msaouel P, Opyrchal M, Domingo Musibay E, et al. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther. 2013; 13(4):483-502.
3. Son HA, Zhang L, Cuong BK, et al. Combination of vaccine-strain measles and mumps viruses enhances oncolytic activity against human solid malignancies. Cancer Invest. 2018; 36(2):106-117.
4. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014; 32(27):2940-2950.
5. Zoń A, Bednarek I. Cisplatin in ovarian cancer treatment-known limitations in therapy force new solutions. International Journal of Molecular Sciences. 2023; 24(8).
6. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry. 2019; 88:102925.
7. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacological Research. 2016; 106:27-36.
8. Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010; 70(3):875-882.
9. Zhang LF, Tan DQ, Jeyasekharan AD, et al. Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. Cancer Letters. 2014; 354(2):272-280.
10. Toan NL, Hang NT, Luu NK, et al. Combination of vaccine strain measles virus and nimotuzumab in the treatment of laryngeal cancer. Anticancer Research. 2019; 39(7):3727-3737.